HDAC inhibitor

HDAC inhibitors are a class of drugs that inhibit the function of Histone Deacetylase (HDAC), an enzyme that plays a key role in the regulation of gene expression. HDAC inhibitors have been studied for their potential use in the treatment of various types of cancer and other diseases.

Mechanism of Action

HDAC inhibitors work by blocking the activity of HDAC enzymes, which are involved in the removal of acetyl groups from the histone proteins that make up chromatin. This process, known as deacetylation, is a key part of the regulation of gene expression. By inhibiting deacetylation, HDAC inhibitors can alter the expression of genes and potentially slow or stop the growth of cancer cells.

Types of HDAC Inhibitors

There are several types of HDAC inhibitors, including:

• Hydroxamic acid-based inhibitors, such as Vorinostat and Panobinostat
• Benzamide-based inhibitors, such as Entinostat and Mocetinostat
• Cyclic peptide-based inhibitors, such as Romidepsin

Clinical Use

HDAC inhibitors have been approved for use in the treatment of certain types of cancer, including cutaneous T-cell lymphoma and multiple myeloma. They are also being studied for potential use in the treatment of other types of cancer, as well as other diseases such as neurodegenerative diseases and inflammatory diseases.

Side Effects

Like all drugs, HDAC inhibitors can have side effects. These can include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include low blood cell counts, heart problems, and liver problems.

See Also

• Epigenetics
• Histone deacetylase
• Cancer treatment

References

HDAC inhibitor Resources
Latest articles Most recent articles Ongoing trials	Wikipedia